Background: Even although time to treatment has been shown to be a determinant of
mortality in primary angioplasty, the potential benefits are still unclear from early
pharmacological reperfusion by glycoprotein (Gp) IIb‐IIIa inhibitors. Therefore, the aim of this
meta‐analysis was to combine individual data from all randomized trials conducted on
upstream as compared with late peri‐procedural abciximab administration in primary
angioplasty. Methods: The literature was scanned using formal searches of electronic …